Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Protein molecule may improve survival in deadly lung disease

07.05.2014

Researchers at the University of Illinois at Chicago College of Medicine have discovered a protein molecule that seems to slow the progression of pulmonary fibrosis, a progressive lung disease that is often fatal three to five years after diagnosis.

The finding is reported in the American Journal of Respiratory and Critical Care Medicine.

Nearly five million people worldwide are affected by pulmonary fibrosis, which causes the lungs to become covered in fibrous scar tissue and leads to shortness of breath that gets more severe as the disease progresses.

Chronic inflammatory and autoimmune diseases can cause pulmonary fibrosis, as can exposure to asbestos, certain toxic gases, and even radiation therapy to treat lung cancer. Treatment options are limited because once scarring occurs, it is permanent. Lung transplantation remains the only effective treatment, but it is usually reserved for advanced cases.

... more about:
»Protein »UIC »blood »deadly »fibrosis »function »idiopathic »lung »pulmonary

“Finding a new therapeutic target for the treatment of pulmonary fibrosis is exciting, especially because the therapies available generally only slow the disease in very few patients,” said Long Shuang Huang, UIC postdoctoral research associate in pharmacology and first author of the paper.

In previous genetic studies of patients with idiopathic pulmonary fibrosis — where no cause can be identified — the researchers found variations in several genes known to be involved in pulmonary fibrosis, including in the gene coding for a protein called lysocardiolipin acyltransferase, or LYCAT.

To investigate the potential role of LYCAT in pulmonary fibrosis, the researchers measured its levels in the blood of idiopathic pulmonary fibrosis patients. Patients with the highest levels of LYCAT had significantly better lung function and higher three-year survival rates than those with lower levels.

“Since higher LYCAT levels directly correlate with better lung function and outcomes, we think the protein is playing some kind of protective role, or could be slowing the progress of pulmonary fibrosis,” Huang said. “This suggests that boosting LYCAT levels in patients with pulmonary fibrosis may be a viable new therapeutic approach to treating the disease,” Huang said.

The researchers also looked at the role of LYCAT in a mouse model of lung tissue scarring, and found that in mice where the LYCAT gene was knocked out, scar tissue developed more readily compared to mice with the gene. In mice engineered to produce elevated levels of LYCAT the development of scarring was much slower.

Looking for compounds or small molecules that increase the production of LYCAT is the next step for Huang and his colleagues.

Co-authors on the paper are Viswanathan Natarajan, Biji Mathew, Peter Usatyuk, Dr. Evgeny Berdyshev, Dr. Wei Zhang, Yanmin Zhang, Sekhar Reddy, Dr. Anantha Harijith and Dr. Jalees Rehman of UIC; Haiquan Li, Tong Zhou, Dr. Yves Lussier and Dr. Joe Garcia of the University of Arizona; Yutong Zhao and Dr. Naftali Kaminski of the University of Pittsburgh; Shwu-Fan Ma and Dr. Imre Noth of the University of Chicago; and Dr. Sainath Kotha, Travis Gurney and Narasimham Parinandi of the Ohio State University.

The research was funded by National Institutes of Health grants P01-HL98050 and R01-GM094220, the Bernie Mac Foundation and the Pulmonary Fibrosis Foundation.

Sharon Parmet | University of Illinois at Chicago
Further information:
http://news.uic.edu/protein-molecule-may-improve-survival-in-deadly-lung-disease

Further reports about: Protein UIC blood deadly fibrosis function idiopathic lung pulmonary

More articles from Life Sciences:

nachricht The balancing act: An enzyme that links endocytosis to membrane recycling
07.12.2016 | National Centre for Biological Sciences

nachricht Transforming plant cells from generalists to specialists
07.12.2016 | Duke University

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Significantly more productivity in USP lasers

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

NTU scientists build new ultrasound device using 3-D printing technology

07.12.2016 | Health and Medicine

The balancing act: An enzyme that links endocytosis to membrane recycling

07.12.2016 | Life Sciences

How to turn white fat brown

07.12.2016 | Health and Medicine

VideoLinks
B2B-VideoLinks
More VideoLinks >>>